Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
Devens, MA, USA — Veranova, a global leader in the development and manufacture of specialty and complex active pharmaceutical ingredients (API) for the pharmaceutical and biotech sectors, announced today that a routine current Good Manufacturing Practice (cGMP) surveillance inspection of Veranova’s Devens, Massachusetts site, completed by the Food and Drug Administration (FDA) New England District on July 31, 2025, concluded without any Form 483s and with a “No Action Indicated” (NAI) classification. This result demonstrates Veranova’s commitment to driving the highest standards of qu
Need to move faster from preclinical to first-in-human? CMC timelines for IND/CTA submissions can make or break a development plan. In this webinar, our CMC and regulatory experts will share how to avoid common bottlenecks and build submission strategies aligned with both FDA and EMA expectations.
o What typically causes delays when filing in both the US and EU?
o How can early CMC planning shorten your submission timeline?
o What support can you tap into from regulators today?
A fantastic opportunity has arisen for a Principal Scientist – Discovery & Translational Biology to join a high-potential drug-development start-up, who are focussed on developing new oncology therapeutics that significantly improve overall survival for patients with a high unmet need. Our client is at the cutting edge of oncology therapeutics, triggering a new wave in target discovery by using proprietary algorithms to identify novel protein fingerprints from a comprehensive membrane protein database.
We are currently looking for a Senior GMP Production Scientist to join a leading biopharmaceutical CDMO based in the South West of the UK to join their team.
Our client specialises in GMP manufacturing of advanced therapy and biologic products. As a Senior GMP Production Scientist, you will take the lead in supervising GMP manufacturing operations for a range of clinical products. This includes overseeing production teams, supporting technology transfer, and ensuring compliance across ATMP and biologics projects.
We are recruiting a Principal Scientist, Non-Clinical PKPD, to join a leading Pharmaceutical company based in the Berkshire area for 12 months. As the Principal Scientist, Non-Clinical PKPD, you will be responsible for driving the quantitative integrated strategy of pharmacokinetics and pharmacology to bring differentiated solutions to patients.
KEY DUTIES AND RESPONSIBILITIES:
Your duties as the Principal Scientist, Non-Clinical PKPD will be varied however the key duties and responsibilities are as follows:
R&D procurement might seem straightforward, but behind the scenes, small mistakes can cause big headaches for labs. Mismanaged orders, unexpected product delays, and budget overruns can derail even the best-laid research plans.
The good news? With a little insight and a few process tweaks, many common pitfalls are easy to avoid. Let’s take a look at the top lab procurement mistakes and how you can sidestep them to keep your research moving forward without disruption.
In an era when precision is paramount, the latest research published in Nature Reviews Drug Discovery has reignited conversations around the need for ultra-high-quality antibody libraries in drug development.
Cybercriminals are increasingly targeting life sciences firms - drawn by valuable IP, sensitive data, and complex, digitally connected supply chains. A successful attack can halt operations, leak critical assets, and damage hard-earned trust.
This webinar explores the unique cyber risks facing the life sciences sector and what can be done to reduce exposure, improve resilience, and how to respond effectively when the worst happens.
Why Attend?
Understand why life sciences is a top target - and how attackers are exploiting sector-specific vulnerabilities.
Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee.